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Activating mutations in NOTCH1 are present in over 50% of
human T-cell lymphoblastic leukemia (T-ALL) samples and
inhibition of NOTCH1 signaling with c-secretase inhibitors (GSI)
has emerged as a potential therapeutic strategy for the
treatment of this disease. Here, we report a new human T-cell
lymphoma line CUTLL1, which expresses high levels of
activated NOTCH1 and is extremely sensitive to c-secretase
inhibitors treatment. CUTLL1 cells harbor a t(7;9)(q34;q34)
translocation which induces the expression of a TCRB-NOTCH1
fusion transcript encoding a membrane-bound truncated form
of the NOTCH1 receptor. GSI treatment of CUTLL1 cells blocked
NOTCH1 processing and caused rapid clearance of activated
intracellular NOTCH1. Loss of NOTCH1 activity induced a gene
expression signature characterized by the downregulation of
NOTCH1 target genes such as HES1 and NOTCH3. In contrast
with most human T-ALL cell lines with activating mutations in
NOTCH1, CUTLL1 cells showed a robust cellular phenotype
upon GSI treatment characterized by G1 cell cycle arrest and
increased apoptosis. These results show that the CUTLL1 cell
line has a strong dependence on NOTCH1 signaling for
proliferation and survival and supports that T-ALL patients
whose tumors harbor t(7;9) should be included in clinical trials
testing the therapeutic efficacy NOTCH1 inhibition with GSIs.
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published online 11 May 2006
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Introduction
T-cell lymphoblastic leukemia (T-ALL) is an aggressive hemato-
logic tumor characterized by a high prevalence of activating
mutations in the NOTCH1 gene.1 The NOTCH signaling
pathway plays a critical role in the hematopoietic system by
maintaining stem cell homeostasis and participating in multiple
stages of T-cell development.2 During early hematopoiesis,
NOTCH signaling is required for the commitment of multipotent
hematopoietic progenitors to the T-cell lineage.3–6 Thus,
immunodeficient mice reconstituted with bone marrow pro-
genitors expressing a constitutively active form of Notch1 show
ectopic T-cell development in the bone marrow and fail to
produce B lymphocytes.5 Conversely, mice harboring a condi-
tional deletion of NOTCH1 in hematopoietic progenitors fail to
develop T-cells, and show ectopic B-cell development in the
thymus.6 In addition to this early role in T-lineage commitment,
NOTCH signaling participates in essential processes at multiple
stages of thymocyte development.7 Thus, NOTCH1 activity (i) is
required for progression through the early DN1, DN2 and DN3
stages of thymocyte development;8 (ii) participates in the
regulation of TCRB gene rearrangement;9 (iii) regulates lineage
decisions between ab and gd lineages;10 and (iv) at least in some
systems, between CD4 and CD8 T-cell lineages.11–14
The NOTCH1 receptor is a class I heterodimeric transmem-
brane protein comprised of an extracellular and a transmem-
brane subunit which in the resting receptor are noncovalently
associated through a dimerization domain. Activation of the
NOTCH1 receptor occurs when NOTCH ligands of the Jagged
and Delta-like family bind to the extracellular subunit of
NOTCH1. Ligand binding induces dissociation of the two
subunits of the receptor and initiates the proteolytic cleavage of
the transmembrane subunit, first by an ADAM metalloprotease
and subsequently by the g-secretase complex, which releases
the cytoplasmic portion of the receptor from the membrane.
Cleaved intracellular NOTCH (ICN) translocates to the nucleus
and binds to CSL, a DNA-binding factor, to form a transcrip-
tional complex which activates the expression of target genes.
Transcriptional activation by the ICN is coupled with phosphor-
ylation of its carboxy-terminus PEST domain and proteasomal
degradation of the protein.15
The first evidence linking aberrant NOTCH1 signaling to the
pathogenesis of T-ALL came from the characterization of the
t(7;9)(q34;q34.3) chromosomal translocation, a rare recurrent
rearrangement identified in the SUPT1 cell line and present in
o1% of human T-ALL cases.16 This translocation juxtaposes a
truncated NOTCH1 gene next to the TCRB locus, leading to the
aberrant expression of an intracellular constitutively active form
of NOTCH1.16 In contrast with the rare occurrence of the t(7;9)
translocation, activating mutations in the NOTCH1 gene are
found in over 50% of patients with T-cell lymphoblastic
leukemias and lymphomas, making it the most prevalent
oncogene in the pathogenesis of this disease.1 Activating
mutations in NOTCH1 typically involve the dimerization and
PEST domains of the receptor. Heterodimerization domain (HD)
mutations disrupt the interaction between the extracellular and
transmembrane subunits of NOTCH1 and are predicted to
induce ligand independent activation of the receptor. Mutations
in the PEST domain of NOTCH1 generate carboxy-terminus
truncated forms of the receptor which, upon ligand interaction,
are predicted to generate ICN forms resistant to proteosomal
degradation.1
Although most of the existent T-ALL cell lines harbor
activating mutations in NOTCH1, most of them fail to show
clear cellular responses to the inhibition of NOTCH signaling.1
This is in contrast with mouse cell lines established from
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lymphomas harboring NOTCH1 mutations, which respond with
rapid cell cycle arrest and apoptosis to inhibition of NOTCH1
with g-secretase inhibitors (GSI).17 As part of our effort to
develop better tools for understanding the role of NOTCH1 in
T-cell malignancies, we have established a new cell line that we
named Columbia University T-cell Lymphoblastic Lymphoma 1
(CUTLL1) which has unique features for the characterization of
oncogenic NOTCH1. Columbia University T-cell Lymphoblas-
tic Lymphoma 1 cells show an immature T-cell phenotype and
harbor a t(7;9)(q34;q34) translocation resulting in juxtaposition
of the TCRB and NOTCH1 loci. In contrast with the original
t(7;9)(q34;q34) present in SUPT1 cells, this rearrangement
generates a fusion transcript encoding a truncated but mem-
brane-bound form of NOTCH1. In addition, CUTLL1 cells are
highly sensitive to inhibition of the NOTCH signaling pathway
with GSIs. These results show that T-cell tumors harboring a
t(7;9)(q34;q34) may be amenable to treatment with GSIs and
highlight the value of CUTLL1 cells for the functional
characterization of the NOTCH signaling pathway in T-ALL.
Material and methods
Patient material
Lymphoma cells from a pleural effusion in a pediatric patient
with T-cell lymphoblastic disease at relapse were obtained from
Morgan Stanley Children’s Hospital of New York-Presbyterian/
Columbia University Medical Center. Informed consent and
approval by the institutional review board were obtained
according to general guidelines.
Establishment and maintenance of the CUTLL1 cell line
Pleural effusion cells (105) were plated in three wells of a
24-well plate in RPMI 1640 supplemented with 20% fetal calf
serum (FCS), penicillin, streptomycin, and L-glutamine at 371C
in a 5% CO2 humidified environment. At 1 week after plating,
cultures showed fibroblast looking cells adherant to plastic with
lymphoid cells attached to them. Half of the media was replaced
with fresh media once a week for 5 weeks with slow but
continuous growth of lymphoid cells. After 6 weeks of culture
cells were expanded by weekly 1:2 dilutions. At 2 months after
initial plating robust lymphoid cell growth was observed and the
cells were transferred to six-well plates and subsequently to
culture flasks. The cell line established in this way has been
named CUTLL1 and has been maintained in continuous culture
in RPMI1640 plus 20% FCS for more than 8 months. Columbia
University T-cell Lymphoblastic Lymphoma 1 can be frozen in
RPMI media containing 20% FCS and 10% dimethyl sulfoxide
and thawed back in culture which is most successful if seeded in
their own conditioned media.
Karyotype and Fluorescence in situ hybridization
analysis
Metaphase chromosome preparations made from CUTLL1 cell
line were subjected to G banding and karyotype analysis
following standard procedures. Two PAC clones RP11-370H5
and CTD-3242B16, which span the NOTCH1 gene were
obtained from Invitrogen. DNA was labeled by nick-translation
using spectrum orange dUTP fluorochrome (Vysis, Downers
Grove, IL, USA). A spectrum green-labeled alpha-satellite
chromosome 9 centromeric probe was obtained from Vysis
(Downers Grove, IL, USA). Fluorescence in situ hybridization
was performed by standard methods on cells used for
cytogenetic analysis. Hybridization signals were scored on at
least 20 metaphase spreads on diamino-phenylindole-stained
slides using the Cytovision Imaging system attached to a Nikon
Eclipse 600 microscope (Applied Imaging, Santa Clara, CA,
USA).
Immunophenotypic analysis
Flow cytometry analysis of CUTLL1 cells was performed after 6
months of in vitro culture. Cells were stained with four-color
antibody cocktails that included anti-CD1a, -CD2, -CD3, -CD4,
-CD5, -CD7, -CD8, -CD10, -CD13, -CD16/56, -CD19, -CD33,
-CD34, -CD45, -CD117, -TCR ab and -TCR gd (BD BioSciences,
San Jose, CA, USA). Cytoplasmic staining with anti-TdT (Beck-
man Coulter, Miami, FA, USA) antibody was performed using
Fix-and-Perm reagents, according to the manufacturer’s instruc-
tions (Caltag Laboratories, Burlingame, CA, USA).
DNA fingerprinting
The genetic identity of the derived cell line with the original
primary lymphoma cells from the patient was confirmed by
analysing 14 tetranucleotide short tandem repeat loci, one
pentanucleotide repeat locus (Penta, Germany) and the Amelo-
genin locus using the PowerPlexR 16 System (Promega,
Madison, WI, USA). Genomic DNA isolated from CUTLL1 cells
and from the corresponding primary T-cell lymphoblastic
lymphoma sample was amplified following the manufacturer’s
instructions. The fluorescent products were analysed by
capillary electrophoresis in a ABI PRISM310 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The results were
analysed using GeneMapper v3.0 analysis software.
50 RACE amplification of aberrant NOTCH1 transcripts
Messenger RNA (mRNA) was extracted from CUTLL1 cells using
the Nucleotrap mRNA extraction kit from Clontech, and 50RACE
was performed with the SMART RACE kit (Clontech, Mountain
View, CA, USA) using a oligogucleotide primer complementary
to the sequence of exon 29 of the NOTCH1 gene (50-TCGTC
CATGAGGGCACCGTCTGAAG-30).
PCR amplification and sequence analysis the
TCRB-NOTCH1 rearrangement
Total genomic DNA from primary T-cell lymphoblastic lym-
phoma cells and from the CUTLL1 cell line was extracted using
the Puregenet Cell and Tissue kit (Gentra, Minneapolis, MN,
USA). PCR amplification and sequence analysis of genomic
sequences spanning the TCRB-NOTCH1 rearrangement was
performed using TCRBJ2S4 (50-GGACCCGGCTCTCAGTGCT-30)
and NOTCH1 Exon 28 (50-TCCCGCCCTCCAAAATAAGG-30)
primers using the High Fidelity PCR System (Roche, Indianapo-
lis, IN, USA) following the manufacturer’s instructions.
Proliferation, apoptosis and cell cycle analysis
Duplicate cultures of CUTLL1 cells were seeded at 5 104 cells/
ml and treated with 500 nM Compound E or vehicle (DMSO).
Cell growth was analysed every 48 h using a colorimetric MTT
assay (MTT Cell Proliferation Kit I, Roche). Cell cycle distribu-
tion was performed by assessment of DNA content using
PI staining as previously described.18 Apoptosis was quantified
by flow cytometry by AnnexinV/PI statining using the Annexin
V: flurescein isothiocyanate Apoptosis Detection Kit I (BD-
Pharmingen, San Diego, CA, USA).
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Microarray hybridization of triplicate CUTLL1 cultures treated
with GSI (500 nM Compound E) or vehicle (DMSO) for 24 h was
performed using Affymetrix U133plus2 arrays following stan-
dard procedures. Interarray intensity differences were normal-
ized with Dchip (http://biosun1.harvard.edu/complab/dchip/).
Unsupervised hierarchical clustering was performed with
Dchip. Supervised Nearest-neighbor analysis of genes asso-
ciated with GSI treatment versus control vehicle (DMSO)
treatment were identified by signal-to-noise nearest-neighbor
analysis performed with Genecluster 2.0 (http://www.broad.mit.
edu/cancer/software/genecluster2/gc2.html) on genes that
showed at least two fold differences between maximum and
minimum values and an absolute difference of at least 100 U.
Results
Establishment and culture of CUTLL1, a new immature
T-cell line
A new cell line was established by in vitro culture of
lymphoblast cells obtained from a pleural effusion sample of a
14-year-old male diagnosed with T-cell lymphoblastic lympho-
ma at relapse. This cell line was named CUTLL1 for Columbia
University T-cell Lymphoblastic Lymphoma 1 and has been
maintained in continuous culture for more than 8 months.
CUTLL1 cells show robust growth in vitro with a doubling time
of 48–72 h and can be frozen and thawed successfully using
their own conditioned media. Microsatellite fingerprinting
results from CUTLL1 cells and the primary lymphoma sample
used to establish this line showed that they share a unique DNA
fingerprint. Fingerprint results and allele sizes for CUTLL1 cells
and the primary lymphoma cells are provided in the supple-
mental material (Table S1 and Supplementary Figure 1). This
result demonstrates that CUTLL1 is in fact a new T-ALL cell line
established from this patient sample and rules out the possibility
that it was the result of accidental cross contamination of this
culture with a different leukemia cell line.
Immunophenotypic analysis of CUTLL1 cells demonstrated
coexpression of CD4 and CD8 as well as CD2, CD5, CD7,
surface CD3 and TCRab (Figure 1). Markers associated to B
(CD19), NK (CD16/56) or myelomonocytic (CD13, CD33 and
CD63) lineage were negative. CUTLL1 cells showed partial
expression of CD10 (31%) and CD1a (10%) markers. They
expressed TdT and were negative for the early hematopoietic
marker CD34.
CUTLL1 is a new T-cell line with the t(7;9) translocation
involving the NOTCH1 locus
Cytogenetic analysis of CUTLL1 cells showed a hyperdiploid
karyotype [50, XY, t(7;9),þ 16,þ 18,þ 20,þ 21] with a char-
acteristic t(7;9)(q34;q34) translocation (Figure 2a and b). This
recurrent chromosomal rearrangement typically involves the
Figure 1 Immunophenotypic characterization of CUTLL1 cell line. CUTLL1 cells were stained with the indicated antibodies and analysed by flow
cytometry. High expression of CD3, CD4, CD8 and TCRab indicate cell arrest at the immature cortical thymocyte stage of development.
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TCRB locus in chromosome 7q34 and the NOTCH1 gene in
9q34, and is found in less than 1% of T-cell lymphoblastic
tumors. Fluorescence in situ hybridization analysis with 9q34
PAC clones spanning the NOTCH1 gene showed a split signal
which was translocated to chromosome 7q confirming the
involvement of the NOTCH1 locus in the t(7;9) translocation
(Figure 2c). This result strongly suggested that CUTLL1 cells may
express a truncated form of NOTCH1. To test this hypothesis,
we performed a 50RACE amplification of the NOTCH1 gene in
CUTLL1 cells using a primer located in exon 29 of NOTCH1,
which encodes the first intracellular region of the receptor. This
experiment amplified a single PCR band corresponding to a
truncated NOTCH1 transcript which spanned NOTCH1 exons
29 and 28 followed by the J2S4 sequence of the TCRB gene
(Figure 2d and e). This chimeric transcript encodes a truncated
form of NOTCH1 which retains the transmembrane region of
the receptor followed by a extracellular stub encoded by exon
28 and a short peptide derived from the TCRB sequence.
Importantly, truncated forms of NOTCH1 lacking most of the
extracellular fraction of the receptor but retaining the transmem-
brane domain are constitutively cleaved by the g-secretase
complex resulting in aberrant NOTCH1 signaling.19
PCR amplification of genomic DNA with primers located in
the J2S4 sequence of the TCRB gene and in exon 28 of NOTCH1
amplified a 1.6 kb band both in CUTLL1 cells and in the primary
lymphoma sample used to establish the cell line (Figure 2f),
demonstrating that the TCRB-NOTCH1 rearrangement was in
fact originally present in the primary cells from the patient and is
not a secondary event acquired during the in vitro immortaliza-
tion of the CUTLL1 cells. Sequence analysis of the rearranged
genomic fragment confirmed the presence of a chromosomal
breakpoint in intron 27 of NOTCH1 joined to TCRB sequences
from chromosome 7 by a stretch of nine extra bases. The
predicted breakpoint positions were flanked by heptamer and
nonamer sequences with homology to RAG consensus recom-
bination sequences separated from the breakpoint by 16 bases
(Figure 2e). These features are characteristic of rearrangements
mediated by the RAG recombinase during thymocyte develop-
ment and strongly suggest that a recombination error during
aberrant TCRB rearrangement may have been responsible for
the generation of the t(7;9).
CUTLL1 cells have a characteristic gene expression
signature
Gene expression profiling with oligonucleotide microarrays
showed that CUTLL1 cells have a unique gene expression
signature when compared with seven other well characterized
Figure 2 Cytogenetic and molecular characterization of the CUTLL1 cell line. (a, b) Karyotype analysis of CUTLL1 cells demonstrated the
presence of a t(7;9)(q34;q34). (c) Double color FISH with a centromeric chromosome 9 probe (green) and a PAC probe containing the NOTCH1
locus (red) shows a split signal demonstrating the involvement of NOTCH1 in the rearrangement. (d) Sequence of 50 RACE amplification of
NOTCH1 demonstrating the presence of a TCRB-NOTCH1 fusion transcript. (e) Schematic representation of the TCRB-NOTCH1 genomic
rearrangement in CUTLL1 cells. Sequences from the TCRB locus in chromosome 7 (blue) are joined to sequences from the NOTCH1 locus in
chromosome 9 (red) by a stretch of nine bases introduced during the rearrangement. Sequences flanking the breakpoint with homology to
heptamer and nonamer rag recombination sequences are underlined. (f) PCR analysis of genomic DNA from CUTLL1 cells and the corresponding
primary lymphoma cells demonstrates the existence of the TCRB-NOTCH1 rearrangement in the cell line and primary patient material.
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T-cell lymphoblastic cell lines. Unsupervised hierarchical
clustering demonstrated that CUTLL1 cells are more related to
the HPB-ALL cell line (Figure 3) and to other T-ALL cell lines
such as ALL-SIL, DND41, KOPTK1 and TALL1 that show
decreased proliferation and G1 cell cycle arrest when treated
with GSI than to cell lines which fail to show a growth
phenotype upon GSI treatment such as CCRF-CEM and
RPMI8402.
CUTLL1 cells have high levels of NOTCH1 activity
which is blocked by treatment with a GSI
A dual mechanism of activation of NOTCH1, is generated by
the presence of the t(7,9) in T-cell progenitors. First, strong
enhancer elements in the vicinity of the TCR locus are predicted
to induce high levels of NOTCH1 expression; and second,
truncated NOTCH1 transcripts generate constitutively active
forms of the receptor that signal in the absence of ligand.
Consistent with this model, CUTLL1 cells harbor high levels of
intracellular activated NOTCH1 protein (NOTCH1IC) measured
by Western blot with an antibody (Val1774, Cell Signaling,
Danvers, MA, USA) that specifically recognizes the g-secretase
cleaved active form of NOTCH1 (Figure 4a and b).
The original t(7;9) translocation identified in SUPT1 cells
generates a cytoplasmic form of NOTCH1 which lacks the
transmembrane domain and therefore is not blocked by GSI.
However, the retention of the sequences encoding the
transmembrane domain of NOTCH1 in the rearranged transcript
expressed in CUTLL1 cells prompted us to test the effects of GSI
in this cell line. Treatment of CUTLL1 cells with the GSI
Compound E for 30 min induced a rapid reduction in the levels
of NOTCH1IC with complete clearance of activated NOTCH1
Figure 3 Gene expression profiling of CUTLL1 and T-ALL cell lines. Hierarchical clustering of microarray gene expression data from duplicate
samples from eight T-ALL cell lines. Clusters of genes upregulated in CUTLL1 cells are shown in the right. Relative gene expression levels are color
coded with red indicating higher levels of expression and blue lower levels of gene expression.
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by Western blot after 4 h (Figure 4a). NOTCH1 inhibition was
sustained for the duration of the treatment with Compound E at
least up to 4 days (data not shown). Inhibition of NOTCH1
signaling in CUTLL1 cells by GSI was dose dependent, with
complete clearance of NOTCH1IC after 24 h with doses as low
as 10 nM of Compound E (Figure 4b). These results demonstrate
that the t(7;9) present in CUTLL1 cells generates a constitutively
active but membrane bound form of NOTCH1 whose activity
requires processing by the g-secretase complex rendering
NOTCH1 signaling in these cells susceptible to inhibition
by GSI.
GSI inhibition of NOTCH1 signaling induces cell cycle
arrest and apoptosis in CUTLL1 cells
To test if sustained high levels of NOTCH1 signaling were
required for the maintenance of the leukemic phenotype in
CUTLL1 cells we evaluated the effect of Compound E on cell
proliferation and survival in this cell line. Treatment of CUTLL1
cells with Compound E drastically impaired cell proliferation by
4 days of treatment (Figure 5a). This reduction in cell growth
resulted from a combination of cell cycle arrest and increased
apoptosis. Thus, treatment of CUTLL1 cells with compound E
induced reduction in S and G2/M phases of the cell cycle and
accumulation of cells in G1 after 3 days of treatment. This effect
in cell cycle progression was accompanied by increased cell
death. Apoptosis (Annexin Vþ /PI cells) increased from 5.6 to
9.4% and cell viability (AnnexinV/PI cells) decreased from 80
to 66%. Thus, in contrast with most human T-ALL cell lines
harboring activating mutations in NOTCH1, which show weak
proliferative responses and no induction of apoptosis upon GSI
treatment, CUTLL1 cells require continuous NOTCH1 signaling
for proliferation and survival.
GSI treatment of CUTLL1 cell induces changes in gene
expression consistent with NOTCH inactivation
To further characterize the transcriptional response of CUTLL1
cells to inhibition of NOTCH1 signaling, we analysed the gene
expression profiles of cells treated with Compound E or vehicle
only (DMSO) for 24 h using oligonucleotide microarrays. As
shown previously, treatment of CUTLL1 cells with Compound E
for 24 h induces complete clearance of intracellular activated
NOTCH1, but still precedes the occurrence of cell cycle arrest
and the induction of apoptosis. Supervised analysis of micro-
array data revealed a total of 41 genes that were consistently
downregulated and 20 genes which were consistently upregu-
lated over two fold upon GSI treatment (Figure 5c). Importantly,
genes downregulated after NOTCH1 inhibition included
NOTCH1 target genes such as HES1 and NOTCH3 and the
MYC and ID1 transcription factor oncogenes. Genes upregu-
lated over two fold in CUTLL1 cells after GSI treatment included
Figure 4 GSI treatment blocks activation of NOTCH1 in CUTLL1 cell lines. The effect of GSI in the levels of activated NOTCH1 in CUTLL1 cells
NOTCH1 was analysed by Western blot using the NOTCH1 Val1744 antibody (Cell Signaling Inc.) which recognizes only the activated form of
NOTCH1 after cleavage by g-secretase complex. (a) Time course Western blot analysis of activated NOTCH1 in CUTLL1 cells treated with GSI
(CompE 500 nM). (b) Dose-dependent inactivation of NOTCH1 signaling in CUTLL1 cells treated with serial dilutions of CompE for 24 h.
(c) Nearest-neighbor analysis of microarray gene expression data in CUTLL1 cells treated for 24 h with CompE or vehicle only (DMSO). Relative
gene expression levels are color coded with red indicating higher levels of expression and blue lower levels of gene expression. Top genes
upregulated and downregulated upon GSI treatment are shown.
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T-cell differentiation markers such as TCRA and important
signaling molecules such as FYB-120/130, CaM kinase II delta,
the dual specific phosphatase 6 and the serum/glucocorticoid
regulated kinase genes.
NOTCH1 cooperative oncogenes and tumor
suppressors in CUTLL1 cells
Activation of NOTCH1 in T-ALL is one of several events that
contributes to the multistep transformation of T-cell progenitors.
Thus, activating mutations in NOTCH1 are found in leukemic
cells expressing other transcription factor oncogenes such as
TAL1, LYL1, HOX11, HOX11L2, LMO1 or LMO2.1 Quantitative
RT–PCR analysis of T-ALL transcription factor oncogenes in
CUTLL1 cells showed that this cell line has a very high level of
expression of HES1, a bHLH factor regulated by NOTCH1 and
lacks significant expression of other T-ALL transcription factor
oncogenes such as HOX11, HOX11L2, TAL1, LMO1 or LMO2
(data not shown).
Sequence analysis of the TP53 gene demonstrated the
presence of a heterozygous G to A mutation in position 994,
which results in the substitution of arginine 248 for glutamine in
the DNA-binding domain of this tumor suppressor (Figure 6b).
Importantly, analysis of the IARC TP53 mutation database at
http://www-p53.iarc.fr/P53main.html, revealed that TP53 muta-
tions in this position are frequent in human cancer and that this
exact amino acid change has been reported in 674 human
tumors including numerous lung, breast, stomach, esophagus,
bladder, pancreas and colon carcinomas, as well as in 12 Li-
Fraumeni families. Sequence analysis of DNA from the primary
lymphoma cells used to establish the CUTLL1 cell line showed
that the 248 arginine to glutamine mutation was originally
Figure 5 Impaired proliferation cell cycle arrest and apoptosis in CUTLL1 cells treated with a GSI. (a) Analysis of cell growth in CUTLL1 cell
treated with GSI (CompE 500 nM) or vehicle (DMSO) using an MTT based assay. (b) Cell cycle analysis of CUTLL1 cells after treatment with GSI
(CompE) or vehicle (DMSO). Cell cycle was analysed daily by assessment of propidium iodide incorporation and FACS analysis. (c) Increased
apoptosis in CUTLL1 cells treated with Compound E. Cells were treated with compound E 500 nM and apoptosis was quantified by flow cytometry
after Annexin V-FITC/PI staining. Figures in the plot show percentage of live, apoptotic and dead cells in control (DMSO) and GSI (CompE) treated
cells.
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present in these cells and is not a secondary event acquired
during immortalization of CUTLL1 cells in vitro (Figure 6c). In
addition, analysis of TP53 transcripts shows that the 994 A
mutant allele is monoallelically expressed in the CUTLL1 cell
line (Figure 6d).
Discussion
T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive
hematologic cancer that accounts for 10 to 15% of pediatric and
25% of adult ALL cases.20,21 Despite recent progress in the
treatment of this disease the prognosis of T-ALL patients with
primary resistant or relapsed disease is very poor, underscoring
the need to develop more effective antileukemic drugs.22–26 The
recent identification of activating mutations in NOTCH1 in over
50% of T-ALL patients demonstrates that the NOTCH1 signaling
pathway plays a critical role in the pathogenesis of human
T-ALL. Thus, inhibition of aberrant NOTCH1 signaling with GSIs
to block a critical activation-associated proteolytic cleavage of
the NOTCH1 receptor, is emerging as a promising novel strategy
for the treatment of T-ALL.
Treatment of human T-ALL cell lines harboring activating
mutations in NOTCH1 with GSIs abrogates NOTCH1 signaling
effectively. However, most of human T-ALL cell lines show no
apparent cellular phenotype in response to the loss of NOTCH1
signaling. Even in those cases in which inhibition of NOTCH1
signaling induces cell cycle arrest, these responses are modest
and are only apparent after relatively long treatments with GSI.
In contrast with these results, recent reports have shown that
mouse cell lymphoma lines harboring similar activating muta-
tions in Notch1 are highly sensitive to GSI and show marked
growth arrest and apoptosis upon Notch inhibition. This
observation suggest that human cell lines which have been in
culture for several years may have acquired additional muta-
tions that render NOTCH1 signaling dispensable for growth in
vitro, while the more recently established mouse lines still
require high levels of activated NOTCH1 for maintenance of
their tumor phenotype.
Here, we report a new human T-cell lymphoblastic lympho-
ma cell line, CUTLL1, with robust cell growth arrest and
apoptotic responses upon inhibition of NOTCH1 signaling with
GSIs. The CUTLL1 cell line has an immature T-cell phenotype
and harbors a characteristic t(7;9). Molecular characterization of
this chromosomal rearrangement showed the presence of a
translocation involving TCRB and NOTCH1 genes that gen-
erates a fusion transcript containing TCRB sequences followed
by NOTCH1 sequences distal to intron 27. The TCRB-NOTCH1
fusion gene present in CUTLL1 cells encodes a truncated but still
membrane bound form of NOTCH1. Similar N-terminus
truncated forms of NOTCH1 have been previously found and
shown to be constitutively cleaved from the membrane by the
g-secretase complex generating high levels of intracellular
activated NOTCH1.
In addition to this TCRB-NOTCH1 rearrangement both
CUTLL1 cells and the relapsed patient sample harbor a
heterozygous mutation in DNA-binding domain of TP53.
Interestingly, analysis of TP53 transcripts showed that this
mutant allele is monoallelically expressed in the CUTLL1 cell
line. In contrast TP53 mutations are present in only 5% of T-ALL
at diagnosis but have been found to be more frequent after
relapse, suggesting that they are selected during chemotherapy
and contribute to treatment failure.
Aberrant NOTCH1 signaling in CUTLL1 cells is dependent on
g-secretase processing of the receptor and can be effectively
blocked with GSIs. This is in contrast with SUPT1 cells, a
previously described t(7;9) leukemia cell line that constitutively
expresses truncated cytoplasmic forms of NOTCH1IC which do
not require g-secretase activity for signaling.
Inhibition of NOTCH1 signaling with GSIs in CUTLL1 cells
impairs cell proliferation inducing G1 cell cycle arrest and
increased apoptosis. Importantly these cellular responses occur
in the absence of the TP53 tumor suppressor gene. Cellular
responses to GSI treatment are preceded by marked transcrip-
tional changes which include the downregulation of NOTCH1
direct target genes such as HES1 and NOTCH3. Importantly, the
gene expression signature induced by NOTCH1 inhibition in
CUTLL1 cells includes important genes involved in the
regulation of cell growth, proliferation and survival which may
mediate the cell cycle arrest and apoptosis induced by GSIs.
Conclusion
In summary, we have established a new T-LL cell line, CUTLL1,
harboring a t(7;9) and expressing a constitutively active but
membrane-bound form of NOTCH1. These findings support
that, in contrast with previous observations, NOTCH1 signaling
can be inhibited with GSIs in patients harboring the t(7;9)
Figure 6 Monoallelic expression of mutant TP53 in CUTLL1 cells.
Sequence analysis of exon 7 of the TP53 tumor suppressor gene shows
the presence of a heterozygous G to A mutation in position 994
present in genomic DNA the CUTLL1 cell line (b), and in the original
primary lymphoma sample (c). Sequence analysis of TP53 cDNA from
CUTLL1 cells, shows that the 994A mutant allele is monolallelically
expressed in this cell line (d).
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translocation and that these patients might benefit from
experimental treatments with GSIs. Finally, the CUTLL1 cell
line represents a valuable novel tool for the characterization of
the NOTCH signaling pathway and for the elucidation of the
transcriptional network initiated by oncogenic NOTCH1 in
human T-cell precursors.
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